A cancer drug that is often used off-label to treat age-related macular degeneration (AMD) appears to be as effective as a far more costly medication used to treat the condition, according to findings from a new study comparing the 2 drugs (CATT Research Group. N Engl J Med. doi: 10.1056/NEJMoa1102673 [published online ahead of print April 28, 2011). Both drugs target vascular endothelial growth factor, a cytokine that plays a key role in blood vessel growth.
Stephenson J. Cancer Drug Offers Effective, Cheaper Option for AMD. JAMA. 2011;305(20):2053-2054. doi:10.1001/jama.2011.685